Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

Fineline Cube Apr 21, 2026
Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Fineline Cube Apr 21, 2026
Company Deals

CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China

Fineline Cube Jul 4, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement...

Company Deals

Amgen Secures Commercialization Rights for Avacopan in Asia and Latin America

Fineline Cube Jul 4, 2024

Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, has entered into a licensing agreement with CSL...

Company Deals

GSK Secures Global Rights to CureVac’s mRNA Vaccine Candidates in Expanded Partnership

Fineline Cube Jul 4, 2024

GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership...

Company Deals

China’s HiRO Expands US Presence with Acquisition of New Jersey-Based DeltaMed Solutions

Fineline Cube Jul 4, 2024

Harvest Integrated Research Organization (HiRO), a China-based ’boutique’ Contract Research Organization (CRO), has expanded its...

Company Drug

LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China

Fineline Cube Jul 4, 2024

LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd...

Company Drug

AstraZeneca’s Voydeya Receives South Korean Approval for PNH Treatment

Fineline Cube Jul 4, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has reportedly secured market approval in South...

Company Deals

Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round

Fineline Cube Jul 3, 2024

Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series...

Company Drug

Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment

Fineline Cube Jul 3, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...

Company

Novartis Launches Construction of First Radioligand Manufacturing Site in China

Fineline Cube Jul 3, 2024

Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, has initiated construction on its second manufacturing...

Company Drug

Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital

Fineline Cube Jul 3, 2024

Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...

Company Deals Medical Device

Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor

Fineline Cube Jul 3, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Drug

China’s Jiangsu Hengrui First to Market Generic Exparel in the US with FDA ANDA Approval

Fineline Cube Jul 3, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Shanghai Henlius Biotech Advances Serplulimab Phase III Trial for First-Line Metastatic Colorectal Cancer

Fineline Cube Jul 3, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...

Company Drug

MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru

Fineline Cube Jul 3, 2024

MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...

Company Drug

Legend Biotech’s Carvykti Shows Significant Overall Survival Improvement in Phase III CARTITUDE-4 Study

Fineline Cube Jul 3, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has announced positive results from the CARTITUDE-4 study, a global,...

Company Drug

Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval

Fineline Cube Jul 3, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration...

Company Drug

Johnson & Johnson’s Talvey Gets Green Light in South Korea for Multiple Myeloma

Fineline Cube Jul 3, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that its subsidiary Janssen Korea has received...

Company Policy / Regulatory

LEK Consulting’s Survey Reveals Biosecure Act’s Impact on Life Sciences Companies

Fineline Cube Jul 3, 2024

LEK Consulting, a UK/US firm, has published the results of a global survey aimed at...

Company Deals

Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin

Fineline Cube Jul 2, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its...

Company Drug

Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals

Fineline Cube Jul 2, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...

Posts pagination

1 … 324 325 326 … 654

Recent updates

  • Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab
  • Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma
  • Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development
  • China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive
  • FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.